Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Shares Outstanding (Weighted Average) (2019 - 2025)

Immunocore Holdings' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $50.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 0.71% year-over-year to $50.3 million; the TTM value through Dec 2025 reached $50.3 million, up 0.71%, while the annual FY2025 figure was $50.3 million, 0.71% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $50.3 million at Immunocore Holdings, roughly flat from $50.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $50.3 million in Q4 2025 and bottomed at $48.2 million in Q1 2023.
  • The 3-year median for Shares Outstanding (Weighted Average) is $50.0 million (2024), against an average of $49.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 3.51% in 2024 before it rose 0.42% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $48.9 million in 2023, then grew by 2.25% to $50.0 million in 2024, then increased by 0.71% to $50.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Shares Outstanding (Weighted Average) are $50.3 million (Q4 2025), $50.3 million (Q3 2025), and $50.3 million (Q2 2025).